JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.27

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.16

Max

3.29

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+30.37% upside

Dividendes

By Dow Jones

Prochains Résultats

17 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

159M

1.2B

Ouverture précédente

3.27

Clôture précédente

3.27

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 févr. 2026, 00:00 UTC

Actions en Tendance

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 févr. 2026, 22:55 UTC

Résultats

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 févr. 2026, 21:44 UTC

Résultats

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 févr. 2026, 21:39 UTC

Résultats

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 févr. 2026, 00:00 UTC

Résultats

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 févr. 2026, 00:00 UTC

Résultats

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 févr. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 févr. 2026, 23:45 UTC

Résultats

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 févr. 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 févr. 2026, 22:59 UTC

Acquisitions, Fusions, Rachats

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 févr. 2026, 22:30 UTC

Résultats

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 févr. 2026, 22:30 UTC

Résultats

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 févr. 2026, 22:21 UTC

Résultats

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 févr. 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 févr. 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 févr. 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4 févr. 2026, 21:53 UTC

Résultats

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 févr. 2026, 21:51 UTC

Résultats

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 févr. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

4 févr. 2026, 21:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

4 févr. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 févr. 2026, 21:45 UTC

Résultats

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 févr. 2026, 21:44 UTC

Résultats

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 févr. 2026, 21:43 UTC

Résultats

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 févr. 2026, 21:41 UTC

Résultats

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 févr. 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 févr. 2026, 21:30 UTC

Résultats

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 févr. 2026, 21:30 UTC

Résultats

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 févr. 2026, 21:30 UTC

Résultats

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

30.37% hausse

Prévisions sur 12 Mois

Moyen 4.25 USD  30.37%

Haut 4.5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat